

PRESS RELEASE
4 March 2026

Benenden Hospital first in the UK to reach landmark 500th Arthrosamid® treatment for knee osteoarthritis



Benenden, Kent – Benenden Hospital, the leading private hospital near Cranbrook in Kent, has this week proudly celebrated treating over 500 patients with Arthrosamid®, an innovative long-lasting^{1,2} hydrogel injection to help patients suffering from knee osteoarthritis. The hospital is the first in the UK to achieve this milestone.

Benenden Hospital launched the service in 2024, offering suitable patients the non-surgical minimally invasive treatment, which involves injecting a hydrogel directly into the knee joint, helping to reduce pain and improve mobility. It offers an effective alternative for those with mild to moderate knee degeneration who may not yet require surgery.

To celebrate the milestone, Consultant Orthopaedic Surgeons Mr Alex Chipperfield and Mr Matthew Oliver, Hospital Director Claire Harley and Director of Clinical Services Ali Turner were joined by members of the hospital's Theatre, Pharmacy, Private Patients and

Marketing teams and representatives from developer and manufacturer Contura Orthopaedics for a presentation and cake-cutting.

Claire Harley, Hospital Director, said:

"This is a phenomenal milestone for our all our teams involved, from Theatres to Pharmacy and Outpatients. It is a true multidisciplinary approach, and they have worked incredibly hard to collectively deliver a service that has had an enormous impact on the quality of life for hundreds of people.

"This landmark number reflects the very high standards of care and quality of patient experience we offer. The Contura team have been fabulous to work with, and I am immensely proud of our staff and consultants and thank them for the expertise and commitment they brought to this success."

Alex Chipperfield, Medical Director and Consultant Orthopaedic Surgeon, said:

"Arthrosamid® feels like a generational product. I have been in orthopaedics for 30 years and do not recall another treatment that has resonated this much and triggered such interest from both clinicians and patients. Arthrosamid® is supported by solid clinical evidence and the results are reproducible in the real world. It's a powerful treatment against knee pain and arthritis. It is a privilege to offer this non-surgical injection and to work in partnership with Contura to deliver our 500th case."

Rakesh Tailor, CEO of Contura Orthopaedics Ltd, added:

"We're thrilled that Benenden Hospital has reached this incredible milestone.

"At Contura Orthopaedics, our mission has always been to reach as many patients as possible with this transformative treatment. The impact of knee osteoarthritis is huge – it's the fastest growing cause of disability worldwide³ - and it's debilitating for so many people. Until recently, the only option for patients was full knee replacement, a surgery which can be daunting, with long recovery times that have a real impact on work and family life.

"Backed by decades of research⁴ Arthrosamid® provides long-lasting, proven pain relief for knee OA^{1,2} without surgery. The latest data show that Arthrosamid® pain relief is maintained for up to five years after a single treatment session.^{1,2}

"It's an honour to be able to celebrate this achievement alongside the whole team at Benenden Hospital and we look forward to continuing our journey together to redefine treatment for knee osteoarthritis."

For more information about Arthrosamid®, visit <https://www.benendenhospital.org.uk/> or <https://arthrosamid.com/>

About Benenden Hospital

Opened in 1907, Benenden Hospital is an independent hospital with charitable status, providing first-class treatment for a wide range of specialities.

The only private hospital in Kent to be rated Outstanding by the Care Quality Commission (CQC), it offers a wide range of healthcare consultations, treatments and diagnostic services to self-pay patients, [Benenden Health](#) members and those with private health insurance. It also offers some services to NHS patients via the e-referral system.

Providing the highest standards of patient care for over 100 years, the hospital offers fast access to over 250 treatments from highly experienced consultants, supported by dedicated clinicians and specialist teams, in calm and comfortable, modern surroundings.

<https://www.benendenhospital.org.uk/>

About Arthrosamid®

Backed by over two decades of research⁴ Arthrosamid® is 2.5% cross-linked polyacrylamide and 97.5% water.^{5,6} When injected into the knee joint, it transports through the synovial membrane and stays within this soft tissue lining⁷ that becomes stiff and inflamed when you have knee osteoarthritis.⁸ The physical presence of Arthrosamid® in this tissue, softens and restores the elasticity to normal levels,⁹ which reduces the pain you feel over a longer period of time.^{1,2}

Delivered as a single, minimally invasive outpatient procedure,^{5,6} Arthrosamid® is becoming a fast evidence-based, viable and long-lasting alternative to conventional therapies (including partial or total knee replacement surgery) for patients with knee OA. Arthrosamid® has already helped more than 26,0000 patients and is now available in approximately 600 clinics across Europe, Canada, and New Zealand.⁴

You can find out more about Arthrosamid® here: <https://arthrosamid.com/>

References:

1. Bliddal, H., et al. (2025). 5-Year Follow-up. Presented at EKS 2025, Copenhagen.
2. Henriksen, M. (2026). Five-year extension study. J Orthop Surg Res, 21:43.
3. Neogi, T. (2013) The epidemiology and impact of pain in osteoarthritis. Osteoarthritis and Cartilage. Vol 21 (9): 1145-53. DOI:10.1016/j.joca.2013.03.018
4. Data on file
5. Arthrosamid®, Instructions For Use. Release Date March 2022. 10082-003.
6. Arthrosamid, Instructions For Use. Release Date October 2025. 10117-001.
7. Smith, D.M., (2011).
8. Rim Y.A., Ju J.H. (2020). Life. Vol 11(1):3.
9. Wimmer, M. A., et al. 18th ICRS World Congress, Boston, 11-14 October (2025).

OUS/ARTHRO/MAR2026/026

For Further Information	Follow Benenden Hospital
<p>Media contact: Philip Orrell PR & Communications Manager philip.orrell@benenden.org.uk 07720 735934</p>	

To interview a spokesperson from Contura Orthopaedics Ltd, contact Jo Hudson at 0770 948 7959 / 020 7112 4905 or email jo.hudson@trinitypr.co.uk